Public Health
NAFDAC Alerts Nigerians to Four Adulterated, Substandard Medicines Recalled in Pakistan
NAFDAC has alerted healthcare professionals, medicine suppliers and the public to four batches of medicines recalled by Pakistan’s drug regulator over adulteration and quality defects, urging vigilance to prevent their entry and circulation in Nigeria.
The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted healthcare professionals, importers, distributors, retailers and the public to four batches of medicines recalled by Pakistan’s Drug Regulatory Authority of Pakistan (DRAP) over quality concerns.
The products—Nitras tablets, Kadin 2 tablets, Acefyl cough syrup and Loratadine 24 tablets—were identified by DRAP as either adulterated or substandard. NAFDAC said it is monitoring the situation to prevent the affected products from entering or circulating in Nigeria.
According to NAFDAC Public Alert No. 038/2026, released on 18 August 2026, the affected medicines include a batch of Nitras containing glyceryl trinitrate, manufactured by M/s Caraway Pharma, Rawat. Batch 24L069 was classified as substandard.
The alert also covers Kadin 2 tablets containing tizanidine hydrochloride, manufactured by M/s FYNK Pharma, Lahore. Batch 569 was classified as adulterated.
Acefyl cough syrup, containing acefylline piperazine and manufactured by M/s NABIQASIM Industries, Karachi, was also classified as adulterated. The affected batch is ACH479.
The fourth product is Loratadine 24 tablets, containing loratadine and manufactured by M/s Murfy Pharma, Lahore. Batch 24 was classified as adulterated.
NAFDAC directs surveillance across Nigeria
NAFDAC said monitoring is ongoing to ensure the recalled products do not gain entry into Nigeria.
The agency has instructed its zonal directors and state coordinators to conduct surveillance and remove any of the affected products if they are found within their respective areas.
The agency has consequently urged importers, distributors, healthcare facilities and pharmacies to exercise vigilance throughout the pharmaceutical supply chain and avoid procuring or distributing the affected batches if identified.
NAFDAC also advised consumers and healthcare professionals not to buy or use the recalled products and stressed the importance of obtaining medicines only from authorised or licensed suppliers.
Why the alert matters
Substandard and adulterated medicines can pose significant risks because their quality, composition or performance may not meet the required standards. Depending on the nature of the defect, their use may result in treatment failure, reduced therapeutic effectiveness or unexpected adverse reactions.
NAFDAC therefore urged stakeholders to check the authenticity and physical condition of medicines before procurement, distribution or use.
The agency also called on healthcare professionals and members of the public to report suspected sales of substandard or falsified medicines to the nearest NAFDAC office or through its reporting channels.
Suspected cases can also be reported by calling NAFDAC on 0800-162-3322 or by emailing sf.alert@nafdac.gov.ng.
Healthcare professionals and patients who experience suspected adverse events associated with medicinal products are encouraged to report them through NAFDAC’s pharmacovigilance channels.
NAFDAC said surveillance and regulatory action remain ongoing as it works to prevent the affected medicines from entering the Nigerian market.